KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for ClearPoint Neuro (CLPT) over the last 12 years, with Q3 2025 value amounting to $199000.0.

  • ClearPoint Neuro's Capital Expenditures rose 155833.33% to $199000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $736000.0, marking a year-over-year increase of 213030.3%. This contributed to the annual value of $275000.0 for FY2024, which is 6164.57% down from last year.
  • According to the latest figures from Q3 2025, ClearPoint Neuro's Capital Expenditures is $199000.0, which was up 155833.33% from $91000.0 recorded in Q2 2025.
  • Over the past 5 years, ClearPoint Neuro's Capital Expenditures peaked at $323000.0 during Q2 2023, and registered a low of -$35000.0 during Q2 2021.
  • In the last 5 years, ClearPoint Neuro's Capital Expenditures had a median value of $76000.0 in 2022 and averaged $110941.2.
  • As far as peak fluctuations go, ClearPoint Neuro's Capital Expenditures crashed by 9489.36% in 2024, and later surged by 155833.33% in 2025.
  • Quarter analysis of 5 years shows ClearPoint Neuro's Capital Expenditures stood at $38000.0 in 2021, then grew by 2.63% to $39000.0 in 2022, then crashed by 46.15% to $21000.0 in 2023, then surged by 1152.38% to $263000.0 in 2024, then dropped by 24.33% to $199000.0 in 2025.
  • Its last three reported values are $199000.0 in Q3 2025, $91000.0 for Q2 2025, and $183000.0 during Q1 2025.